Richard B Moss

US Patent:

20050032117, Feb 10, 2005

Filed:

Feb 13, 2004

Appl. No.:

10/777683

Inventors:

Richard Moss - Palo Alto CA, US
Akitoshi Ishizaka - Shinagawa-ku, JP
Teruo Kirikae - Shinjuku-ku, JP

International Classification:

G01N033/53

US Classification:

435007100

Abstract:

The invention provides a method for assessment of cystic lung fibrosis (CF) in terms of severity, acuteness, degree of progress, etc. of CF., with high accuracy, high sensitivity, convenience, rapidity, and low cost. The method includes the steps of measuring the level of CAP 18 in a biological sample, and correlating the measurement with CF.

US Patent:

20070049641, Mar 1, 2007

Filed:

Aug 22, 2006

Appl. No.:

11/507706

Inventors:

Rabindra Tirouvanziam - Redwood City CA, US
Lenore Herzenberg - Stanford CA, US
Leonard Herzenberg - Stanford CA, US
Carol Conrad - Menlo Park CA, US
Richard Moss - Woodside CA, US

International Classification:

A61K 31/198

US Classification:

514562000

Abstract:

The present invention relates to pharmaceutical kits and methods to treat lung inflammation and redox imbalance in human cystic fibrosis patients using pharmaceutical compositions containing N-acetylcysteine (NAC), pharmaceutically acceptable salts of N-acetylcysteine, or N-acetylcysteine derivatives. In phase I studies, treatment with oral NAC at a dose of from about 1800 mg/day to about 3000 mg/day for a period of 4 weeks produced significant positive effects, namely, it decreased absolute numbers of white blood cells and neutrophils in the sputum and produced concomitant decreases in sputum neutrophil elastase specific activity and sputum interleukin-8 levels, suggesting an amelioration of lung inflammation in the patients. These effects were associated with an increased total GSH level in whole blood as well increased staining for reduced GSH in blood neutrophils, both of which reflect an amelioration of the redox imbalance in the patients. In ongoing phase II studies, oral NAC at a dose of about 2700 mg/day administered in double-blind manner for 12 weeks showed excellent safety and significantly decreased white blood cells in sputum as compared to placebo.